首页|Bispecific antibody drug conjugates:Making 1+1>2

Bispecific antibody drug conjugates:Making 1+1>2

扫码查看
Bispecific antibody-drug conjugates(BsADCs)represent an innovative therapeutic category amalgamating the merits of antibody-drug conjugates(ADCs)and bispecific antibodies(BsAbs).Posi-tioned as the next-generation ADC approach,BsADCs hold promise for ameliorating extant clinical chal-lenges associated with ADCs,particularly pertaining to issues such as poor internalization,off-target toxicity,and drug resistance.Presently,ten BsADCs are undergoing clinical trials,and initial findings un-derscore the imperative for ongoing refinement.This review initially delves into specific design consid-erations for BsADCs,encompassing target selection,antibody formats,and the linker-payload complex.Subsequent sections delineate the extant progress and challenges encountered by BsADCs,illustrated through pertinent case studies.The amalgamation of BsAbs with ADCs offers a prospective solution to prevailing clinical limitations of ADCs.Nevertheless,the symbiotic interplay among BsAb,linker,and payload necessitates further optimizations and coordination beyond a simplistic"1+1"to effectively surmount the extant challenges facing the BsADC domain.

Bispecific antibody drug conjugatesAntibody drug conjugatesBispecific antibodyTargeted therapySafetyHER2EGFR

Yilin Gu、Zhijia Wang、Yuxi Wang

展开 >

Targeted Tracer Research and Development Laboratory,Institute of Respiratory Health,Frontiers Science Center for Disease-Related Molecular Network,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China

Frontiers Medical Center,Tianfu Jincheng Laboratory,Chengdu 610212,China

国家自然科学基金Sichuan Science and Technology Program,ChinaSupport Program of Science and Technology Department of Sichuan Provincial,ChinaSupport Program of Science and Technology Department of Sichuan Provincial,China

820733182019YFS00032023YFSY00462022NSFSC1365

2024

药学学报(英文版)

药学学报(英文版)

CSTPCD
ISSN:
年,卷(期):2024.14(5)
  • 1